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Highly specialized cells, the thyrocytes, express a
thyroid-specific set of genes for thyroglobulin (Tg),
thyroperoxidase, and the transcription factors
TTF-1, TTF-2, and Pax-8. The implication of the
small GTPase RhoA in TSH-mediated proliferation
of FRTL-5 rat thyroid cells has been previously
demonstrated. To further analyze RhoA function in
thyroid cell proliferation and differentiation pat-
terns, we combined transient and stable transfec-
tion assays to express different mutant RhoA
forms in FRTL-5 cells. Constitutively active RhoA
(FRTL-5-RhoA QL cells) exhibited a fibroblast-like
phenotype with organized actin fibers, whereas
cells expressing the RhoA negative dominant phe-
notype (FRTL-5-RhoA N19 cells) present a rounded
morphology and lose normal cytoskeletal architec-
ture. In addition, expression of the constitutively
active form of RhoA results in TSH-independent
proliferation and anchorage-independent growth
and induces tumors when inoculated in nude mice.
Interestingly, FRTL-5-RhoA QL cells express less
Tg and TTF-1 than wild-type FRTL-5 (FRTL-5-
vector) or FRTL-5-RhoA N19, suggesting a loss at
the differentiation stage. This effect is mediated, at
least in part, by a decrease in TTF-1 activity, since
transient or stable expression of RhoA QL results
in a reduction in the activity of the wild-type Tg
promoter as well as an artificial promoter the ac-
tivation of which depends exclusively on TTF-1.
The similarity between RhoA effects and thyroid
transformation by Ras suggests that RhoA may act
as a downstream effector of Ras; in fact, the dom-
inant negative RhoA N19 abolished the down-
regulatory effect of Ras V12 over the Tg promoter.
Taken together, these results show for the first
time that active RhoA is able to transform FRTL-5
cells and that this effect is coupled to a loss of
thyroid differentiation due to impaired TTF-1
activity. (Molecular Endocrinology 16: 33–44, 2002)
THE RAS PROTEINS are a group of guanine nucle-otide-binding proteins that function as molecular
switches in many cellular signaling pathways, interact-
ing with a wide spectrum of regulators and down-
stream effectors; they produce a broad range of cel-
lular responses such as proliferation, differentiation, or
apoptosis (1, 2). The expression of transforming Ras
oncogenes interacts with the establishment and main-
tenance of cellular differentiation in different tissues
(3–6), including the thyroid. In this tissue, Ras inhibits
the expression of thyroid-specific genes and confers a
proliferative advantage over normal thyroid cells (7–
11). Ras transformation in the specialized epithelial
thyroid cell line FRTL-5 suppresses the expression of
thyroid differentiation markers such as thyroglobulin
(Tg), thyroperoxidase (TPO), and iodine uptake (12). In
parallel, the transcription factors controlling thyroid
gene expression, such as TTF-1, TTF-2, or Pax-8, are
either not present or inactive (10, 13, 14). In K-ras-
transformed thyroid cells (FRTL-5-K-ras), both TTF-1
and Pax-8 mRNA are undetectable, whereas in H-ras
(FRTL-5-H-ras), TTF-1 is present at normal levels and
maintains its DNA binding properties, although the
cells lack the ability to express Tg and TPO (11). Sev-
eral proteins have been identified as potential effectors
of Ras signaling, including Raf/MAPK kinase/ERK,
RalGDS, and PI3K, although the mechanism of Ras-
mediated inhibition of thyroid cell differentiation re-
mains essentially unclear.
Another Ras protein family that includes RhoA,
Rac1, and Cdc42 plays a pivotal role in controlling
many cellular functions, such as cytokinesis, motility,
proliferation, and apoptosis (15). These three proteins
cooperate with Raf in cell transformation, and the
dominant negative forms of RhoA and Rac1 can inhibit
Ras-induced transformation, indicating an essential
function in this process (16–20). Moreover, Rac1 and
RhoA have been implicated in the morphogenic and
mitogenic responses to transformation by oncogenic
Ras (21, 22). In the context of thyroid cells, the positive
effects of RhoA in thyroid cell proliferation have been
related to its role in p27Kip1 degradation (23). Among
other functions, p27Kip1 has been implicated in G1
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arrest induced by inhibitors of 3-hydroxy-3-methylglu-
taryl-coenzyme-A reductase (23). These inhibitors in-
terfere with cell cycle progression by suppressing the
isoprenylation of proteins (24), and RhoA is a class of
isoprenylated small GTPases proposed to be involved
in G1/S transition in FRTL-5 cells (23, 24). We recently
confirmed these results and demonstrated that over-
expression of either the dominant negative form RhoA
N19 or the specific inhibitor of RhoA activity, the ex-
oenzyme C3, thus inhibits FRTL-5 cell proliferation,
causing G1 arrest (25).
In the present study, we combined transient and
stable expression of different mutant RhoA forms as
tools to study the role of this protein in the differenti-
ation of FRTL-5 thyroid cells. We found that activation
of RhoA induces TSH-independent proliferation, mor-
phological transformation, anchorage-independent
growth, and tumorigenesis when cells are injected into
nude mice. These effects could be mediated by the
activation of c-fos and c-jun, the expression of which
is probably central in cell proliferation control and is
also necessary for neoplastic transformation by a va-
riety of oncogenes (26, 27). In addition, RhoA activa-
tion results in a less differentiated thyroid phenotype,
decreasing Tg and TTF-1 gene expression by blocking
transactivation of the Tg promoter through inhibition of
TTF-1 transcriptional activity. These results demon-
strate for the first time that RhoA induces transforma-
tion of FRTL-5 thyroid cells.
RESULTS
Generation and Analysis of Stable FRTL-5 Cells
Expressing Different Mutant Forms of
RhoA Protein
The rat thyroid follicular cell line FRTL-5 provides a
useful model with which to study growth and differen-
tiation of specialized epithelial cells. To analyze the
role of RhoA protein in the differentiation pattern of
thyroid cells, FRTL-5 cells were stably transfected with
either an AU5-tagged dominant positive form of RhoA
(RhoA QL) (28), an AU5-tagged dominant negative
form of RhoA (RhoA N19) (29), or with AU5-RhoAQL
together with an expression vector for C3 toxin which
ribosylates and inactivates RhoA (28, 30). Transfected
FRTL-5 clones were tested for exogenous RhoA ex-
pression by immunoblotting analysis of total cell ex-
tracts using anti-AU5 or -RhoA antibodies. Three rep-
resentative neomycin-resistant clones referred as
FRTL-5-RhoA QL, RhoA N19, and RhoA QL-C3 were
selected for further study (Fig. 1A). As has been de-
scribed extensively, the small GTP-binding protein
RhoA regulates the assembly of focal adhesion and
actin stress fibers in response to growth factors (15).
We thus analyzed the possible morphological changes
due to overexpression of the different RhoA mutant
forms. Phase contrast photomicroscopy of early pas-
sage FRTL-5 clones indicated that, in the presence of
6H complete medium, FRTL-5-RhoA QL cells present
a fibroblast-like appearance compared with neomy-
cin-resistant FRTL-5 cells carrying control vector
(FRTL-5-vector) (Fig. 1B). In addition, the cellular limits
within the colonies are clearly distinguished. Con-
versely, FRTL-5-RhoA N19 cells present a rounded
shape and diffuse cell-to-cell limits within colonies.
Interestingly, no fibroblast-like morphology was ob-
served when the RhoA inhibitor, the exoenzyme C3,
was expressed together with RhoA QL. In fact, these
cells show a rounded morphology similar to those
expressing the dominant negative form N19 (Fig. 1B).
We support these results by immunofluorescence
using fluorescein-conjugated phalloidin to visualize
the actin cytoskeleton. FRTL-5-RhoA QL cells present
a more protrusive appearance compared with FRTL-
5-vector cells, whereas FRTL-5-RhoA N19 and RhoA
QL-C3 cells show a redistribution of the actin fibers,
lose their normal cytoskeleton organization and round
up (Fig. 1C).
RhoA Activation Induces a Proliferative
Advantage and TSH-Independent Growth
In addition to the morphological changes induced by
RhoA, results from several laboratories demonstrate
that this protein is involved in TSH-mediated thyroid
cell proliferation (23–25). Inhibition of RhoA activity by
the C3 exoenzyme or by transient expression of dom-
inant negative RhoA N19 thus decreases FRTL-5 cell
proliferation, causing G1 arrest in the cell cycle. To
confirm the role of RhoA in proliferation, growth curves
were performed in stably transfected cells cultured
alone or in the presence of TSH (see Materials and
Methods).
In the presence of TSH (6H medium), overexpres-
sion of constitutively active RhoA (FRTL-5-RhoA QL
cells) induces a proliferative advantage compared with
controls (FRTL-5-vector cells), whereas expression of
the dominant negative mutant form of RhoA (FRTL-5-
RhoA N19 cells) decreases cell proliferation (Fig. 2B).
Interestingly, FRTL-5-RhoA QL cells grow in the ab-
sence of TSH with a growth rate similar to that seen in
the presence of the hormone, while the FRTL-5-vector
or -RhoA N19 cells barely grow in the absence of TSH
(Fig. 2A). These data confirm that RhoA activation
induces TSH-independent growth in FRTL-5 cells. Cy-
tometric analysis of FRTL-5-RhoA N19 clones dem-
onstrated a decrease in the S phase of the cell cycle as
a consequence of G1 arrest (not shown), confirming
previous results (25).
RhoA Activation Induces Transformation in Vitro
and Increases the Tumorigenicity of FRTL-5
Thyroid Cells
FRTL-5 cells are considered a normal nontumorigenic
cell line, although contradictory results are found
throughout the bibliography (12, 31). The tumorigenic-
ity of FRTL-5 cells is thus conditioned by clonal vari-
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ability, TSH levels in nude mice, and cell passage
number (12, 31, 32). Rho proteins have transforming
and oncogenic potential in a cell type-specific manner
(16–20). Cells expressing constitutively active mutants
of Rac and RhoA display enhanced growth in low
serum, are anchorage independent, and induce tumor
formation when inoculated into nude mice (20). In ad-
dition, Rac and Rho proteins are essential for trans-
formation by Ras (16, 18).
To assess RhoA-dependent FRTL-5 transformation,
the ability of each cell line was tested to form colonies
in semisolid medium in the presence or absence of
TSH; only cells expressing the active mutant form of
RhoA (RhoA QL) were able to grow in soft agar (Table
1). The number of colonies was similar in the absence
or presence of TSH, again demonstrating the TSH-
independent growth of cells expressing RhoA QL.
To test the role of RhoA protein in FRTL-5 tumori-
genicity, we inoculated FRTL-5-RhoA QL and FRTL-
5-RhoA N19 cells, as well as FRTL-5-vector cells, into
nude mice (2  106 cells). Four weeks later, we ob-
served tumors in the FRTL-5-RhoA QL cell-inoculated
group, whereas the groups inoculated with FRTL-5-
vector cells or FRTL-5-RhoA N19 cells remained nor-
mal (Table 1). These results indicate that RhoA induces
FRTL-5 cell transformation and tumorigenesis. Ex-
cised tumors were analyzed histologically as de-
scribed in Materials and Methods. FRTL-5-RhoA QL-
inoculated mice developed large tumors located in the
dermis (Fig. 3A), whereas control or FRTL-5-RhoA
N19-inoculated mice remained normal. Tumors were
highly undifferentiated and infiltrative. Tumor cells
were poorly differentiated, showing small cytoplasm
and large nuclei with abundant mitosis (Fig. 3B). They
Fig. 1. Expression of RhoA Mutants in Thyroid Follicular Cells
A, FRTL-5 cells were stably transfected with vector alone or harboring the AU5-tagged-RhoA QL, AU5-tagged RhoA N19, or
exoenzyme C3 plus the AU5-tagged RhoA QL. Neomycin-resistant colonies were isolated and analyzed by immunoblotting, using
anti-AU5 or anti-RhoA antibodies. A 30-kDa band corresponding to exogenous RhoA protein was detected in several independent
clones. FRTL-5 positive clones studied (vector, RhoA QL, RhoA N19, and RhoA QL-C3) were selected for further studies. B,
General morphology of the above clones obtained by phase contrast photomicroscopy, of early-passage cells, 2 d after plating.
Magnification, 100. C, Cells were stained with fluorescein isothiocyanate-phalloidin to visualize the actin cytoskeleton. Mag-
nification, 100.
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grew in a solid, diffuse pattern, with neither follicles nor
papillary structures. Infiltration was observed mainly
as satellite tumor nodules (Fig. 3C). Bromodeoxyuri-
dine (BrdU) immunostaining showed that proliferative
cells were located mainly in peripheral regions of the
tumor (Fig. 3D); satellite tumor nodules were highly
proliferative, mainly in the peripheral area (Fig. 3E).
Detailed necropsy of the mice revealed no other rele-
vant effects.
Molecular mechanisms leading to transformation
and tumorigenicity are complex and involve the acti-
vation of different signaling pathways, as well as the
expression of a set of genes the induction of which
may play a role regulating these processes. In an
attempt to understand some of the mechanisms re-
sponsible for FRTL-5 RhoA QL transformation, we an-
alyzed the levels of cAMP as the main signaling path-
way controlling thyroid cell growth (33) and because
most thyroid tumors present increased levels of this
second messenger (34). The results obtained show
similar levels of cAMP in FRTL-5 vector (370  25
fmol/well), RhoA QL (374  20 fmol/well), and RhoA
N19 (365  19 fmol/well) cells maintained in 6H me-
dium, suggesting that the upstream effector cAMP is
Fig. 2. Proliferative Activity of Thyroid Follicular Cells Carry-
ing Constitutively Active RhoA QL or Inactive RhoA N19
FRTL-5 clones were maintained in the absence of TSH (5H
medium) for 3 d. From then on, cells were cultured either in
the same medium (panel A) or in a medium with TSH (6H
medium) (panel B). Cell number was monitored every 3 d for
12 consecutive days, and viable cell number is represented.
The data are the mean  SD of three independent experi-
ments.
Table 1. RhoA Activation Induces Transformation in Vitro
and Tumorigenesis in Vivo
Cell Line
Colonies in Soft Agar
(n)
Tumors in Nude Mice
4 Wk after Injection
(n)TSH TSH
FRTL-5 vector 0 0 0/12
FRTL-5 RhoA QL 129  8 140  12 12/12
FRTL-5 RhoA N19 0 0 0/12
Values for number of colonies are the mean  SD obtained
from three independent experiments of each cell type. Tumor
frequency is expressed as number of mice with tumors/total
number of mice.
Fig. 3. Histological Analysis of Tumors from FRTL-5-RhoA
QL-Inoculated Cells into Nude Mice
A, General view of hematoxylin-eosin-stained large nodu-
lar tumor derived from FRTL-5-RhoA QL-inoculated cells (8
magnification). The tumor is well defined, unencapsulated,
and localized in the dermis. It presents a solid growth pattern
with moderate blood vessel proliferation. B, Hematoxylin-
eosin staining of the peripheral area of an undifferentiated,
solid tumor derived from FRTL-5-RhoA QL cells, with ana-
plastic cells with small cytoplasm (125 magnification). C,
Anti-BrdU-hematoxylin staining of the peripheral area of the
previous figure showing abundant highly stained, BrdU-
positive cells (intense brown color) (125 magnification). D,
Anti-BrdU-hematoxylin staining of an infiltrative, satellite
nodule formed in the peripheral area of an undifferentiated
tumor. The arrow indicates the augmented area shown in Fig.
3E (50 magnification). E, Anti-BrdU-hematoxylin staining of
the peripheral area of the infiltrative nodule shown in Fig. 3D.
Note that most of the nuclei are highly stained with BrdU
(300 magnification).
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not responsible for either growth independence or cell
transformation induced by RhoA activation. To identify
downstream genes that could explain the above phe-
nomena, we analyzed the levels of early response
genes such as c-fos and c-jun. The election of these
genes was based on previous reports demonstrating
their involvement in RhoA signaling (35, 36). Western
blot assays using nuclear protein extracts detect in-
creased levels of c-Fos and c-Jun in FRTL-5 cells
expressing the constitutively active form of RhoA (Fig.
4); the active phosphorylated form of c-Jun (P-Ser
63-c-Jun) is also increased after RhoA QL overexpres-
sion. These data suggest that the activation of these
oncogenes is involved in RhoA transformation process
in FRTL-5 cells.
Activation of RhoA Is Sufficient to Affect Thyroid
Cell Differentiation
Cell transformation is usually coupled to a loss of
differentiated phenotype. Transformation of FRTL-5
cells with two oncogenic Ras forms, Harvey (FRTL-5-
H-Ras) and Kirnstein Ras (FRTL-5-K-Ras), has been
studied extensively. The work of several groups has
showed that Ras transformation of FRTL-5 cells re-
sults in loss of iodine uptake, as well as in Tg and TPO
gene expression (7–11). To study further the effect of
RhoA activation in FRTL-5 cells, we measured expres-
sion of thyroid-specific mRNA for one of the critical
thyroid-specific markers, Tg, and for its transcription
factor TTF-1, in FRTL-5 clones carrying the constitu-
tively active RhoA QL or the dominant negative RhoA
N19. Tg and TTF-1 mRNA levels were not significantly
affected by inactivation of RhoA protein (FRTL-5-RhoA
N19 cells), whereas activation of RhoA (FRTL-5-RhoA
QL cells) clearly decreased both Tg and TTF-1 mRNA
levels (Fig. 5A). To test whether the RhoA-mediated
decrease in Tg and TTF-1 mRNA levels correlates with
a loss of Tg and TTF-1 protein levels, we performed
Western blot assays using total or nuclear protein
extracts to detect Tg or TTF-1 protein levels, respec-
tively (Fig. 5B). Total protein extracts from FRTL-5-
RhoA QL cells express less Tg than FRTL-5-vector
cells or FRTL-5-RhoA N19 cells. Western blot assays
using nuclear extracts from FRTL-5 cell clones
showed a decrease in TTF-1 protein levels in FRTL-5-
RhoA QL cells (Fig. 5B). Figure 5 shows representative
Northern and Western blots. Similar results were ob-
tained in all stable clones generated.
Transient Active RhoA Expression Represses the
Activity of the Tg Promoter
Several studies have implicated the protein RhoA in
the morphogenic and mitogenic responses to trans-
formation by oncogenic Ras (16, 18). In addition, pre-
vious studies of Ras-mediated transformation have
shown its negative effect in the activity of thyroid-
Fig. 4. c-Fos and c-Jun Expression in Normal and RhoA
Expressing FRTL-5 Cells
Nuclear protein extracts (20 g) from vector, RhoA QL, or
RhoA N19 FRTL-5 clones were analyzed by Western blotting
by use of anti-c-Fos, anti-c-Jun, and anti-P-c-Jun antibodies.
Anti-Sp1 antibody was used as a loading control.
Fig. 5. Tg and TTF-1 Levels in Normal and RhoA-Expressing
FRTL-5 Cells
A, Total RNA (30 g) from stable FRTL-5 clones were
blotted onto nytran membranes and sequentially hybridized
with specific cDNA probes indicated at the right of the panels.
As a loading control, membranes were hybridized with an
actin-labeled probe. B, Total protein extracts (30 g) from
stable FRTL-5 clones were blotted onto protran membranes
and incubated with specific anti-Tg antibody. Antiactin anti-
body was used as a loading control. Nuclear protein extracts
(20 g) from different FRTL-5 clones were immunobloted
with anti-TTF-1 antibody. Anti-Sp1 antibody was used as a
loading control.
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specific promoters (11, 37, 38). Transient expression
of Ras V12 in FRTL-5 cells thus decreases the activity
of TPO, Tg, and sodium iodide symporter gene pro-
moter (38). Our results show that RhoA activation de-
creases Tg and TTF-1 mRNA levels, suggesting tran-
scriptional inhibition of thyroid differentiation. To test
this hypothesis, FRTL-5 cells were transiently trans-
fected with the Tg promoter (TACAT-3) (39, 40), along
with expression vectors encoding for the different
RhoA mutant forms or for C3. Plasmid cytomegalovi-
rus-luciferase (CMV-Luc) was transfected to correct
for transfection efficiency. Cells were lysed 72 h after
transfection, and chloramphenicol acetyltransferase
(CAT) and luciferase activity were measured. Expres-
sion of the dominant positive RhoA QL resulted in
approximately 75% inhibition of Tg promoter activity.
The effect was due to RhoA activation, as it was abol-
ished when cotransfected with its negative dominant
form RhoA N19 or with the exoenzyme C3 (Fig. 6A). As
described by Alberts et al. (41), we confirmed activity
of transfected RhoA mutants by testing the activity of
a construct containing wild-type serum response ele-
ments (not shown).
Tg promoter (TACAT-3) contains three binding sites
for the homeodomain-containing protein TTF-1, which
has been reported as its main transcriptional activator,
although it is also regulated by other transcription
factors (13, 39, 40). To verify that TTF-1 is involved in
the RhoA-induced reduction of the Tg promoter activ-
ity, we used a 5C-CAT reporter gene containing an
artificial promoter carrying five binding sites for TTF-1
placed in tandem upstream of the TATA box (42). This
promoter is regulated exclusively by TTF-1, showing
strong activity in FRTL-5 thyroid cells. In transient
transfection assays, 5C-CAT transcription was sup-
pressed by RhoA QL expression to an extent similar to
that of the wild-type (TACAT-3) Tg promoter. Again,
RhoA N19 or C3 expression reverts RhoA QL inhibition
of 5C-CAT promoter (Fig. 6B). As a control for the
specificity of the transfected plasmids on the Tg pro-
moter, we used the promoterless TATA-CAT vector
(14), the activity of which remained unaffected (not
shown).
Due to the parallelism observed in the inhibition of
TTF-1 transcriptional activity mediated by Ras (11, 13,
38) and RhoA (present study), we asked whether the
dominant negative form of RhoA, the N19 mutant, is
able to revert Ras-induced Tg promoter repression.
FRTL-5 cells were transiently transfected, as de-
scribed above, with the wild-type Tg promoter
(TACAT-3), along with expression vectors encoding
Ras V12, Ras N17, and RhoA N19. Expression of Ras
V12 resulted in 80–90% inhibition of the Tg promoter
activity, and its dominant negative form Ras N17 re-
verted the effect. The dominant negative form RhoA
N19 also reverted the inhibitory effect of Ras V12 on
the Tg promoter (Fig. 7). These results clearly demon-
strate that the Ras effect on the Tg promoter is RhoA
dependent and suggest that RhoA is downstream of
Ras in the control of thyroid differentiated phenotype.
Fig. 6. Effects of RhoA Expression on Tg Promoter Activity
FRTL-5 cells were transiently transfected with a construct
containing the wild-type Tg promoter (TACAT-3) (panel A), or
a construct containing five binding sites for TTF-1 (5C-CAT)
(panel B), and with vectors encoding the different mutant
RhoA forms or the C3 exoenzyme. Plasmid CMV-Luc was
transfected to correct for transfection efficiency. At 72 h after
transfection, cells were lysed, and CAT and luciferase activ-
ities were measured. Promoter activity is calculated as arbi-
trary units relative to the cells transfected with vector alone
(100). The data are the mean  SD of three independent
experiments.
Fig. 7. RhoA N19 Reverts Ras-Mediated Inhibition of Tg
Promoter Activity
FRTL-5 cells were transiently transfected with a construct
containing the wild-type Tg promoter (TACAT-3) and with
expression vectors for Ras V12 alone or together with Ras
N17 or RhoA N19. Plasmid CMV-Luc was transfected to
correct for transfection efficiency. At 72 h after transfection,
cells were lysed, and CAT and luciferase activities were mea-
sured. Promoter activity is calculated as arbitrary units rela-
tive to the cells transfected with vector alone (100). The
data are the mean  SD of three independent experiments.
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Stable RhoA QL Expression Represses TTF-1
Transcriptional Activity in FRTL-5 Cells
To confirm the RhoA-mediated decrease in TTF-1
transcriptional activity in FRTL-5 cells, we performed
similar assays using FRTL-5 cell clones stably ex-
pressing RhoA N19 or RhoA QL. The cells were trans-
fected with 5C-CAT and CMV-Luc; after 72 h cells
were lysed and CAT and luciferase activities mea-
sured. Expression of the constitutively active RhoA QL
clearly inhibits 5C-CAT reporter gene activation,
whereas stable expression of the dominant negative
RhoA N19 form had no effect on the TTF-1 transcrip-
tional activity (Fig. 8A). As a control, we tested 5C-CAT
reporter gene activity in two stable FRTL-5 cell lines
expressing the oncogenic Ras forms, H-ras and K-ras
(12). As extensively described (13, 14), Ras transfor-
mation inhibits TTF-1 transcriptional activity in these
cell lines (Fig. 8A).
TTF-1 transcriptional activity is regulated mainly by
posttranslational modifications such as site-specific
phosphorylation and redox mechanisms (43–45). In
Ras-transformed FRTL-5 cells (FRTL-5-H-ras), Tg ex-
pression is absent due to expression of an inactive
form of TTF-1 (11, 14). To understand the mechanism
of RhoA-mediated dedifferentiation of thyroid cells, we
determined whether RhoA activation affects TTF-1
transcriptional activity. The 5C-CAT reporter was tran-
siently transfected with a vector harboring the TTF-1
cDNA into stable FRTL-5 cell clones expressing either
RhoA QL or RhoA N19. 5C-CAT activity was not af-
fected either in FRTL-5-vector cells or in FRTL-5 N19
cells when TTF-1 was overexpressed (Fig. 8B). This
may be due to the existence of saturated levels of
endogenous active TTF-1, as previously reported in
FRTL-5 cells (14, 43). Interestingly, overexpression of
this transcription factor in FRTL-5-RhoA QL had no
effect in reverting RhoA-mediated inhibition of TTF-1
transcriptional activity, supporting the idea that RhoA
may decrease Tg expression through some posttrans-
lational modifications of TTF-1 protein (Fig. 8B). A
similar phenomenon has been described in FRTL-5-
H-ras cells overexpressing TTF-1 (11, 14).
DISCUSSION
We show that constitutively active RhoA QL trans-
forms FRTL-5 thyroid cells, rendering them more pro-
liferative, tumorigenic, and undifferentiated. As has
been previously demonstrated, RhoA is required for
TSH-mediated thyroid cell proliferation (23, 24). Tran-
sient expression of dominant negative RhoA N19 or
the inhibition of RhoA activity by choleric exoenzyme
C3 decreases thyroid cell proliferation as a conse-
quence of G1 arrest (25). Here we present evidence
that stable expression of the dominant positive form
RhoA QL induces a proliferative advantage in FRTL-5
thyroid cells. Conversely, expression of the dominant
negative RhoA N19 decreases FRTL-5 thyroid cell
proliferation.
The Rho protein subfamily, including RhoA, Rac1,
and Cdc42, are involved in cell shape regulation and
actin filament assembly (46, 47). Lovastatin-induced
inactivation of these proteins causes cell rounding and
actin filament disassembly (48). In several cell types,
spread cellular morphology allowed DNA synthesis,
whereas rounded cells did not proliferate or undergo
apoptosis (49). The analysis of FRTL-5-RhoA QL
clones with phalloidin shows that these cells spread in
a fibroblast-like fashion and display actin stress fibers.
This morphology disappears and becomes rounded,
with a distinct actin distribution, in clones generated
after transfection of expression vectors for C3 exoen-
zyme and RhoA QL, demonstrating that the changes
observed in the cell phenotype are due to the genes
Fig. 8. Effect of Stable RhoA Expression on TTF-1 Tran-
scriptional Activity
A, FRTL-5 cells expressing the different mutant RhoA
forms were transiently transfected with the 5C-CAT construct
containing five specific binding sites for TTF-1. Plasmid
CMV-Luc was transfected to correct for transfection effi-
ciency. As a control, we transfected the 5C-CAT construct in
FRTL-5 cells stably expressing K-ras and H-ras. B, FRTL-5
cells expressing the different mutant RhoA forms were tran-
siently transfected with 5C-CAT, CMV-Luc, and a TTF-1 ex-
pression vector. As a control, we transfected FRTL-5-H-ras.
In both panels (A and B), cells were lysed at 72 h after
transfection, and CAT and luciferase activities were mea-
sured. The promoter activity is calculated as arbitrary units
relative to the cells transfected with vector alone (100). The
data are the mean  SD of three independent experiments.
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transfected and not to an indirect action of the trans-
gene used. FRTL-5-RhoA N19 cells also presented a
rounded cell shape and diffuse cell-to-cell limits. This
altered cell morphology was followed by a decrease in
FRTL-5-RhoA N19 cell proliferation. In this regard, Zhu
et al. (50) reported that for cell cycle progression to
occur, the actin cytoskeleton must be assembled.
These clones could thus be useful to study in greater
detail the links between RhoA-mediated cytoskeletal
rearrangement and its positive effects in thyroid cell
proliferation.
RhoA activation has transforming and oncogenic
potential in some cell lines (21, 22). Fully differentiated
FRTL-5 thyroid cells are considered nontumorigenic,
although they can be rendered so in a single transfor-
mation step by expression of retroviral oncogenes
such as H-ras or K-ras (12). As we show here, RhoA
QL induces in vitro transformation of FRTL-5 cells,
assessed by anchorage- and TSH-independent
growth and tumors when inoculated into nude mice.
Excised tumors revealed highly proliferative infiltrated
carcinomas, suggesting that RhoA induces FRTL-5
thyroid transformation in vivo. We show that RhoA
transformation of FRTL-5 cells is not due to increased
cAMP levels, as has been reported in most thyroid
tumors (34). The expression of c-Fos and c-Jun is
increased in FRTL-5-RhoA QL cells, suggesting that
these two oncogenes may be involved in the cell trans-
formation described here. As has previously been re-
ported, the expression of these two proteins is likely to
play a role in the control of cell proliferation (26, 51), as
they are necessary for cell cycle progression in several
cellular systems and for neoplastic transformation by a
variety of oncogenes (27). Interestingly, phospho-c-
Jun levels are also increased in FRTL-5-RhoA QL
transformed cells. These results open new questions
about whether RhoA activation increases JNK activity
in FRTL-5 cells as has been demonstrated in other
systems (28). All together, these data concur with the
previous observation of the regulation of early gene
expression and cellular transformation elicited by
RhoA.
A general effect in thyroid cell transformation is the
loss of cell differentiation. Oncogenic Ras thus sup-
presses thyroid differentiation marker expression, and
Ras-transformed cells do not express Tg or TPO, do
not respond to TSH, and do not take up iodine (12). In
parallel, the transcription factors controlling the ex-
pression of thyroid-specific genes are either not
present or inactive (10, 11, 13, 14). In K-ras-trans-
formed thyroid cells, both Pax-8 and TTF-1 mRNA are
undetectable, whereas in H-ras-transformed cells,
TTF-1 is present at normal levels and maintains its
binding capacity, although the cells lack the ability to
express Tg and TPO (11, 14). Our results show that
expression of active RhoA decreases Tg mRNA levels,
whereas expression of dominant negative RhoA N19
shows Tg mRNA levels comparable to those of con-
trols (FRTL-5 cells). RhoA expression also decreases
Tg protein levels, confirming that RhoA modifies the
thyroid phenotype affecting Tg expression. The RhoA-
mediated decrease in Tg gene expression may be due
to a lack of activity of TTF-1, a specific transcription
factor involved in Tg gene activation. Our results
clearly demonstrate that active RhoA decreases TTF-1
expression when compared with FRTL-5-RhoA N19
and FRTL-5-vector cells. Moreover, RhoA activation
decreases TTF-1 protein levels in the nucleus, where
this factor activates thyroid-specific promoters. The
fact that overexpression of exogenous TTF-1 in stable
FRTL-5-RhoA QL cells has no effect on Tg promoter
construct activity, together with the observation that
RhoA QL inhibited the effect of TTF-1 in transient
transfection experiments, suggests that RhoA QL af-
fects TTF-1 involving a posttranslational mechanism.
This may account not only for the reduction in Tg
protein levels, but also for the reduction in TTF-1, as
this transcription factor is autoregulated (52). Mecha-
nisms involved in modulating the transcriptional po-
tential of TTF-1 include phosphorylation (43), control
of the redox state (44, 45), and interaction with other
factors (53). Ras repression of the Tg promoter in-
volves changes in TTF-1 phosphorylation (14). The
fact that RhoA N19 reverts the effect of Ras V12 on the
wild-type Tg promoter suggests that RhoA is a down-
stream effector of Ras in this process. Thus, it would
be of interest to test the ability of RhoA to modify the
phosphorylation state of TTF-1. Interestingly, the pro-
tein kinases PKN, MKK3/6, and ERK6 have been pro-
posed as components of a novel signal transduction
pathway involved in the regulation of gene expression
and cellular transformation elicited by RhoA (36).
TTF-1 contains several minimal consensus sequences
for ERK phosphorylation and has been reported to be
phosphorylated by ERK2 (38). Although ERK2 does
not mediate the RhoA effect on NIH-3T3 fibroblasts
(36), the role of this family of kinases in response to
RhoA and its effect in TTF-1 phosphorylation could be
addressed in FRTL-5 cells. However, we cannot rule
out the possibility that TTF-1 may be phosphorylated
by other RhoA effectors.
The new role for RhoA protein in FRTL-5 thyroid
cells increases the complexity of the signal transduc-
tion pathways implicated in the control of thyroid cell
proliferation and function. FRTL-5 thyroid cells depend
mainly on TSH for proliferation (33, 54, 55); this hor-
mone stimulates thyroid cell proliferation through both
PKA-dependent and -independent pathways (25, 56).
After TSH stimulation, downstream effectors such as
Akt (57), Rac1 (38), or RhoA (23–25) are involved in
thyroid cell growth and function. Activation of Akt,
Rac1, or RhoA increases thyroid cell proliferation, al-
though Akt or Rac1 expression has no effect on the
differentiation status of thyroid cells. Here we suggest,
for the first time, a role for RhoA in thyroid differenti-
ation. The similarity between Ras-mediated thyroid
cell transformation, together with our observation that
RhoA N19 reverses the effect of Ras V12 on the Tg
promoter, suggests the existence of cross-talk involv-
ing both proteins, as described previously for other
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cell systems (58). Further studies are needed to ex-
plain in detail the role of RhoA in Ras-mediated thyroid
transformation.
MATERIALS AND METHODS
Cell Culture
Rat thyroid follicular FRTL-5 cells (ATCC CRL 8305; American
Type Culture Collection, Manassas, VA) were kindly provided
by Dr. L. D. Kohn (Edison Biotech Institute, Athens, OH). The
cells had the properties previously described (59, 60), were
diploid, and their doubling time with TSH was 24–36 h. Cells
were maintained in Coon’s modified Ham’s F-12 medium
(Sigma, St. Louis, MO) supplemented with 5% calf serum
(Life Technologies, Inc., Gaithersburg, MD) and six-growth
factor (6H complete medium), including TSH (0.5 mU/ml) and
insulin (10 g/ml) (49). FRTL-5-K-ras and FRTL-5-H-ras cells
were maintained as previously described (11, 12).
Plasmids and Expression Constructs
TACAT-3 corresponds to the wild-type Tg promoter (39, 40).
As a negative control, we used the TATA-CAT plasmid con-
struct corresponding to the wild-type Tg promoter minus the
Sal/I-NheI fragment (39), resulting in only the Tg TATA box
linked to the CAT gene. For detection of TTF-1 transcriptional
activity, the C5E1b-CAT construct (Ref. 42; referred to here
as 5C-CAT) was transiently transfected into FRTL-5 cells. The
5C-CAT construct contains five tandem repeats of the C
binding site for TTF-1 from the Tg promoter and is exclusively
dependent on TTF-1 for transactivation (42). The CMV-Luc
plasmid was used to correct for transfection efficiency (39).
For TTF-1 overexpression assays, we used a vector contain-
ing wild-type TTF-1 (41). The role of RhoA was analyzed with
expression vectors encoding the dominant positive AU5-
tagged-RhoA QL (28), the dominant negative AU5-tagged-
RhoA N19 (29), the dominant negative Ras N17 or positive
Ras V12 (61), or the botulinum C3 exoenzyme (28).
Transfection Assays
FRTL-5 cells were stably transfected by the calcium phos-
phate DNA precipitation method, as described (39, 11).
Briefly, calcium phosphate DNA precipitates were prepared
with 10 g of plasmid DNA containing either constitutively
active mutant AU5-tagged RhoA (RhoA QL) (28) or the dom-
inant negative form of AU5-tagged RhoA (RhoA N19) (29). To
abolish RhoA activation, a stable cell line was generated
transfecting together 5 g of AU5-tagged RhoA QL and 5 g
of the C3 expression vector. In all cases 1 g of plasmid DNA
containing the neomycin resistance gene under the control of
viral long terminal repeat promoter, and 40 g of calf thymus
genomic DNA as carrier (Roche Molecular Biochemicals) was
also cotransfected. Cells were selected with 300 g/ml G418
(Sigma). After 3 wk, G418-resistant colonies were isolated
and expanded.
For transient transfection assays, cells were plated at a
density of 5  105/60 mm diameter tissue culture dish; 48 h
later, TACAT-3, 5C-CAT, TATA-CAT (2.5 g), or CMV-Luc (1
g) reporter plasmids were transfected with the expression
vectors as indicated in the figure legends. After 72 h, cell
extracts were lysed in lysis buffer (10 mM HEPES, pH 7.9, 40
mM NaCl, 0.1 mM EGTA, 0.5 mM dithiothreitol, 5% glycerol,
and 0.5 mM phenylmethylsulfonyl fluoride). Luciferase (Luc)
and chloramphenicol acetyltransferase (CAT) activity were
measured as described (62, 63).
Immunoblotting and Immunofluorescence
Nuclear or total extracts were prepared in sample buffer, and
protein concentration was determined by the Bradford tech-
nique (Bio-Rad Laboratories, Inc., Hercules, CA). Protein
samples were resolved in SDS-PAGE and transferred to Pro-
tran membranes (Schleicher & Schuell, Inc., Keene, NH).
Monoclonal anti-AU5 antibody (0.5 g/ml) used to detect
AU5-tag was purchased from Badco. Polyclonal anti-RhoA
(1 g/ml), anti-actin (1 g/ml), anti-Sp1 (1 g/ml), anti c-Fos
(2 g/ml), anti-c-Jun (1 g/ml), and anti-P-Ser 63-c-Jun
(2 g/ml) antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Anti-Tg antibody (0.5
g/ml) was from DAKO Corp. (Carpinteria, CA), and anti-
TTF-1 antibody (1 g/ml) from Biopat Immunotechnologies
(Italy). Immune complexes were detected with Luminol
reagent as indicated by the manufacturer (Santa Cruz Bio-
technology, Inc.).
For immunofluorescence assays, FRTL-5-vector, FRTL-5-
RhoA QL, FRTL-5-RhoA N19, and FRTL-5-RhoA QL-C3 cells
were fixed in 4% formaldehyde for 30 min, and then perme-
abilized with 0.1% Triton X-100 in PBS. Samples were incu-
bated with fluorescein isothiocyanate-phalloidin (Sigma, 1:40
dilution in PBS) for 1 h at 37 C. Cells were then washed twice
with PBS and mounted on microscope slides. Fluorescence
was visualized in a photomicroscope (Carl Zeiss, Thornwood,
NY) equipped with epifluorescence. Photographs were taken
using Kodak 400 ASA film.
Growth Curve Profiles
To perform growth curves profiles, cells were seeded at a
confluence of 105/100 mm dish and maintained 3 d in the
absence of TSH (5H medium). From then on, cells were
cultured either in medium with TSH, for the 6H curve, or
maintained in 5H medium. Fresh medium (6H or 5H, respec-
tively) was added every 3 d. The number of viable cells was
determined by cell counting every 3 d for 12 consecutive
days. The mean  SD of three independent experiments is
represented.
Anchorage-Independent Growth
Approximately 9,000 cells were seeded in 60-mm petri dishes
in 0.35% noble agar (Sigma) on a 0.5% agar underlayer. Cells
were tested to grow in soft agar containing 6H or 5H medium.
Plates were incubated for 3 wk, during which time fresh
medium (6H or 5H, respectively) was added to the plates
every 3 or 4 d. After crystal violet staining, colonies larger
than 50 m diameter were counted. The mean  SD of three
independent experiments is represented.
Growth of Tumors in Nude Mice
Tumorigenicity was assayed by injecting 2 106 cells sc into
nude mice, which were palpated weekly for tumor develop-
ment. After 4 wk, the animals were killed and tumors excised
for histological analysis under protocols approved by the
Human Research Committee (Vanderbilt University, Nash-
ville, TN). For histopathological analysis (64), tissues were
fixed in 10% buffered formaldehyde for 48 h, embedded in
paraffin, and cut into 6-m serial sections that were stained
with hematoxylin-eosin (Fig. 3), Mason’s trichrome, and pe-
riodic acid Schiff methods (not shown). BrdU staining was
performed as follows: RhoA QL-inoculated mice received 1%
5-bromo-2 deoxyuridine (Sigma) ip 2 h before being killed.
Tumors were removed and sections prepared as for hema-
toxylin-eosin staining. Before immunohistochemistry, sec-
tions were deparaffined, hydrated, and washed with PBS.
PBS was then removed and endogenous peroxidase inhib-
ited using 3% hydrogen peroxidase (10 min, 37 C). Sections
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were blocked in goat serum (Zymed Laboratories, Inc., South
San Francisco, CA) and incubated overnight with a mouse
monoclonal anti-BrdU antibody (Amersham Pharmacia Bio-
tech, Piscataway, NJ). After washing with PBS, sections were
incubated with biotinylated goat antimouse antibody (Biocell)
in 20% human serum PBS buffer. After washing, sections
were incubated with streptavidin-biotin-peroxidase complex
(Zymed Laboratories, Inc.) and developed with diaminoben-
zidine (Sigma). Sections were counterstained with Harris he-
matoxylin, dehydrated in ethanol, and mounted in DePex
(Probus, Barcelona, Spain).
RNA Isolation and Analysis
Total RNA was isolated by the guanidinium-isothiocyanate-
phenol method (65). Total RNA samples were electropho-
resed in 1% agarose gels containing formaldehyde. RNA was
transferred to Nytran membranes (Schleicher & Schuell, Inc.),
and RNA integrity was verified by methylene blue staining of
the blots. Hybridization and washing were performed with
probes specific for Tg (66), TTF-1 (67), or -actin (68) labeled
with [32P]-dCTP by random priming.
cAMP Assays
The Biotrak cAMP competitive enzyme immunoassay system
(Amersham Pharmacia Biotech) was used following manu-
facturer’s instructions for the determination of intracellular
cAMP. Briefly, cells were cultured in 24-well plates (105 cells
per dish) and then lysed, moved to a donkey antirabbit Ig-
precoated microtiter plate and incubated with anti-cAMP
antiserum (2 h, 4 C). Samples were then incubated with
a cAMP-peroxidase-conjugated antibody (1 h, 4 C) and
washed four times with washing buffer. The enzyme sub-
strate was added immediately afterward to all wells and
incubated (1 h, room temperature). Before optical density
determination in a plate reader at 450 nm, the reaction was
terminated by adding 0.1 M sulfuric acid to each well. In
parallel, a standard curve with cAMP concentrations from
12.5–3,200 fmol/well was prepared. Each value represents
the mean  SD of three independent experiments. As control
for assay validation, FRTL-5 cells maintained in 5H and 6H
medium were used, being the cAMP levels 50  7 fmol/well
and 390  30 fmol/well, respectively.
Acknowledgments
We are indebted to Dr. Leonard D. Kohn (Edison Biotech
Institute, Athens, OH) for FRTL-5 cells, to Dr. Silvio Gutkind
(National Cancer Institute, NIH, Bethesda, MD) for the RhoA
QL, RhoA N19, C3, RasV12, and RasN17 expression vectors,
and to Dr. Roberto Di Lauro (Stazione Zoologica, A. Dohrn,
Naples, Italy) for cDNA and expression vectors of TTF-1 as
well as the different Tg promoter constructs. We thank Car-
men Sa´nchez-Palomo for help with the immunohistochemical
techniques and Catherine Mark for her linguistic assistance.
Received December 27, 2000. Accepted August 31, 2001.
Address all correspondence and requests for reprints to:
Dr. Pilar Santisteban, Instituto de Investigaciones Biome´di-
cas, CSIC/UAM, Arturo Duperier, 4, E-28029 Madrid, Spain.
E-mail: psantisteban@iib.uam.es.
This work was supported by DGICYT Grants PM97/0065
and BMC2001-2087, and CAM Grant 08.1/0025/99. D.L.M.
and M.R. are recipients of a fellowship from the Spanish
Ministerio de Educacio´n y Cultura and Ciencia y Tecnologı´a,
respectively.
* D.L.M. and M.R. contributed equally to this work and
both should be considered first authors.
REFERENCES
1. Bourne HR, Sanders DA, McCormick F 1990 The GTPase
superfamily: a conserved switch for diverse cell func-
tions. Nature 348:125–132
2. Bos J L 1997 Ras-like GTP-ases. Biochim Biophys Acta
1333:M19–M31
3. Beug H, Palmieri S, Freudenstein SC, Zentgraf H, Graf T
1992 Hormone-dependent terminal differentiation in vitro
of chicken erythroleukemia cells transformed by mutants
of avian erythroblastosis virus. Cell 28:907–919
4. Fiszman MY, Fuchs P 1975 Temperature-sensitive ex-
pression of differentiation in transformed myoblasts. Na-
ture 254:429–431
5. Olson EN, Spizz G, Tainsky MA 1987 The oncogenic
forms of N-ras or H-ras prevent skeletal myoblast differ-
entiation. Mol Cell Biol 7:2104–2111
6. Schmidt A, Setoyama C, de Crombrugghe B 1985 Reg-
ulation of a collagen gene promoter by the product of
viral mos oncogene. Nature 314:286–289
7. Gallo A, Benusiglio E, Bonapace IM, Feliciello A, Cassano
S, Garbi C, Musti AM, Gottesman ME, Avvedimento EV
1992 v-ras and protein kinase C dedifferentiate thyroid
cells by down-regulating nuclear cAMP-dependent pro-
tein kinase A. Genes Dev 6:1621–1630
8. Gallo A, Feliciello A, Varrone A, Cerillo R, Gottesman ME,
Avvedimento VE 1995 Ki-ras oncogene interferes with
the expression of cyclic AMP-dependent promoters. Cell
Growth Differ 6:91–95
9. Feliciello A, Giuliano P, Porcellini A, Garbi C, Obici S,
Mele E, Angotti E, Grieco D, Amabile G, Cassano S, Li Y,
Musti AM, Rubin CS, Gottesman ME, Avvedimento EV
1996 The v-Ki-Ras oncogene alters cAMP nuclear sig-
naling by regulating the location and the expression of
cAMP-dependent protein kinase II. J Biol Chem 271:
25350–25359
10. Avvedimento VE, Musti AM, Ueffing M, Obici S, Gallo A,
Sanchez M, DeBrasi D, Gottesman ME 1991 Reversible
inhibition of a thyroid-specific trans-acting factor by Ras.
Genes Dev 5:22–28
11. Francis-Lang H, Zannini M, De Felice M, Berlingieri MT,
Fusco A, Di Lauro R 1992 Multiple mechanisms of inter-
ference between transformation and differentiation in
thyroid cells. Mol Cell Biol 12:5793–5800
12. Fusco A, Berlingieri MT, Portella G, Di Fiore PP, Grieco
M, Vecchio G 1987 One- and two-step transformation of
rat thyroid epithelial cells by retroviral oncogenes. Mol
Cell Biol 7:3365–3370
13. Missero C, Cobellis G, De Felice M, Di Lauro R 1998
Molecular events involved in differentiation of thyroid
follicular cells. Mol Cell Endocrinol 140:37–43
14. Velasco JA, Acebro´n A, Zannini M, Martı´n-Pe´rez J, Di
Lauro R, Santisteban P 1998 Ha-ras interference with
thyroid cell differentiation is associated with a down-
regulation of thyroid transcription factor-1 phosphoryla-
tion. Endocrinology 139:2796–2802
15. Van Aelst L, D’Souza-Schorey C 1997 Rho GTPases and
signaling networks. Genes Dev 11:2295–2322
16. Khosravi FR, Solski PA, Clark GJ, Kinch MS, Der CJ 1995
Activation of Rac1, RhoA, and mitogen-activated protein
kinases is required for Ras transformation. Mol Cell Biol
15:6443–6453
17. Qiu RG, Chen J, Kirn D, McCormick F, Symons M 1995
An essential role for Rac in Ras transformation. Nature
374:457–459
18. Qiu RG, Chen J, McCormick F, Symons M 1995 A role for
Rho in Ras transformation. Proc Natl Acad Sci USA
92:11781–11785
19. Qiu RG, Abo A, McCormick F, Symons M 1997 Cdc42
regulates anchorage-independent growth and is neces-
sary for Ras transformation. Mol Cell Biol 17:3449–3458
42 Mol Endocrinol, January 2002, 16(1):33–44 Medina et al. • RhoA and Thyroid
 by on May 20, 2010 mend.endojournals.orgDownloaded from 
20. Lin R, Bagrodia S, Cerione R, Manor D 1997 A novel
Cdc42Hs mutant induces cellular transformation. Curr
Biol 7:794–797
21. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall
A 1992 The small GTP-binding protein rac regulates
growth factor-induced membrane ruffling. Cell 70:
401–410
22. Ridley AJ, Hall A 1992 The small GTP-binding protein
Rho regulates the assembly of focal adhesions and actin
stress fibers in response to growth factors. Cell 70:
389–399
23. Hirai A, Nakamura S, Noguchi Y, Kitagawa M, Tatsuno I,
Oeda T, Hakara, Terano T, Naruyima S, Kohn LD, Saito Y
1997 Geranylgeranylated Rho small GTPase(s) are es-
sential for the degradation of the p27kip1 and facilitate
the progression from G1 to S phase in growth-stimulated
rat FRTL-5 cells. J Biol Chem 272:13–16
24. Noguchi Y, Nakamura S, Yasuda T, Kitagawa M, Kohn
LD, Saito Y, Hirai A 1998 Newly synthesized Rho A, not
Ras, is isoprenylated and translocated to membranes
coincident with progression of the G1 to S phase of
growth-stimulated rat FRTL-5 cells. J Biol Chem 273:
3649–3653
25. Medina DL, Toro MJ, Santisteban P 2000 Somatostatin
interferes with thyrotropin-induced G1-S transition
mediated by PKA and PI3-K: involvement of RhoA
and cyclin E-CDK2 complexes. J Biol Chem 175:
15549–15556
26. Angel P, Karin M 1991 The role of Jun, Fos and the AP-1
complex in cell-proliferation and transformation. Biochim
Biophys Acta 1072:129–157
27. Suzuki T, Murakami M, Onai N, Fukuda E, Hashimoto Y,
Sonobe MH, Kameda T, Ichinose M, Miki K, Iba H 1994
Analysis of AP-1 function in cellular transformation path-
way. J Virol 68:3527–3535
28. Teramoto H, Crespo P, Coso OA, Igishi T, Xu N, Gutkind
S 1996 The small GTP-binding protein Rho activates
c-Jun N-terminal kinases/stress-activated protein ki-
nases in human kidney 293T cells: evidence for a Pak-
independent signaling pathway. J Biol Chem 271:
25731–2573430
29. Crespo P, Bustelo XR, Aaronson DS, Coso OA, Lopez-
Barahona M, Barbacid M, Gutkind JS 1996 Rac-1 de-
pendent stimulation of the JNK/SAPK signaling pathway
by Vav. Oncogene 13:455–460
30. Lerm M, Schmidt G, Aktories K 2000 Bacterial protein
toxins targeting Rho GTPases. FEMS Microbiol Lett
188:1–6
31. Ossendorp FA, Bruning PF, Schuuring EM, Van Den
Brink JA, van der Heide D, De Vijlder JJ, De Bruin TW
1990 Thyrotropin dependent and independent thyroid
cell lines selected from FRTL-5 derived tumors grown in
nude mice. Endocrinology 127:419–430
32. Peter HJ, Gerber H, Studer H, Groscurth P, Zakarija M
1991 Comparison of FRTL-5 cell growth in vitro with that
of xenotransplanted cells and the thyroid of the recipient
mouse. Endocrinology 128:211–219
33. Medina DL, Santisteban P 2000 Thyrotropin-dependent
proliferation of in vitro rat thyroid cell systems. Eur J
Endocrinol 143:161–178
34. Farid NR, Shi Y, Zou M 1994 Molecular basis of thyroid
cancer. Endocr Rev 15:202–232
35. Hill CS, Wynne J, Treisman R 1995 The rho family
GTPases RhoA, Rac1, and CDC42Hs regulates tran-
scriptional activation by SRF. Cell 81:1159–1170
36. Marinissen MJ, Chiariello M, Gutkind JS 2001 Regulation
of gene expression by the small GTPase Rho through the
ERK6 (p38) MAP kinase pathway. Genes Dev 15:
535–553
37. Cobellis G, Missero C, Di Lauro R 1998 Concomitant
activation of MEK-1 and Rac-1 increases the proliferative
potential of thyroid epithelial cells, without affecting their
differentiation. Oncogene 17:2047–2057
38. Missero C, Pirro MT, Di Lauro R 2000 Multiple ras down-
stream pathways mediate functional repression of the
homeobox gene product TTF-1. Mol Cell Biol 20:
2783–2793
39. Sinclair AJ, Lonigro R, Civitareale D, Ghibelli L, Di Lauro
R 1990 The tissue-specific expression of the thyroglob-
ulin gene requires interaction between thyroid-specific
and ubiquitous factors. Eur J Biochem 193:311–318
40. Civitareale D, Lonigro R, Sinclair AJ, Di Lauro R 1989 A
thyroid specific nuclear protein essential for tissue-
specific expression of the thyroglobulin promoter. EMBO
J 8:2537–2542
41. Alberts AS, Geneste O, Treisman R 1998 Activation of
SRF-regulated chromosomal templates by Rho-family
GTPases requires a signal that also induces H4 hyper-
acetylation. Cell 92:475–487
42. De Felice M, Damante G, Zannini M, Francis-Lang H, Di
Lauro R 1995 Redundant domains contribute to the tran-
scriptional activity of the thyroid transcription factor-1.
J Biol Chem 270:26649–26656
43. Zannini M, Acebron A, De Felice M, Arnone MI, Martı´n-
Pe´rez J, Santisteban P, Di Lauro R 1996 Mapping and
functional role of phosphorylation sites in the thyroid
transcription factor-1 (TTF-1). J Biol Chem 271:
2249–2254
44. Arnone MI, Zannini M, Di Lauro R 1995 The DNA binding
activity and the dimerization ability of the thyroid tran-
scription factor 1 are redox regulated. J Biol Chem 270:
12048–12055
45. Kambe F, Nomura Y, Okamoto T, Seo H 1996 Redox
regulation of thyroid-transcription factor, Pax-8 and
TTF-1, is involved in their increased DNA-binding activ-
ities by thyrotropin in rat FRTL-5 cells. Mol Endocrinol
10:801–812
46. Hall A 1998 Rho GTPases and the actin cytoskeleton.
Science 279:509–514
47. Takai Y, Sasaki T, Tanaka K, Nakanishi H 1995 Rho as a
regulator of the cytoskeleton. Trends Biochem Sci 20:
227–231
48. Fenton RG, Kung HF, Longo DL, Smith MR 1992 Regu-
lation of intracellular actin polymerization by prenylated
cellular proteins. J Cell Biol 117:347–356
49. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber
DE 1997 Geometric controls of cell life and death. Sci-
ence 276:1425–1428
50. Zhu X, Ohtsubu M, Bohmer RM, Roberts JM, Assoian RK
1996 Adhesion-dependent cell cycle progression linked
to the expression of cyclin D1, activation of cyclin E-cdk2
and phosphorylation of the retinoblastoma protein. J Cell
Biol 133:391–403
51. Kovary K, Bravo R 1991 The jun and fos protein families
are both required for cell cycle progression in fibroblasts.
Mol Cell Biol 11:4466–4472
52. Oguchi H, Kimura S 1998 Multiple transcripts encoded
by the thyroid-specific enhancer-binding protein
(T/EBP)/thyroid-specific transcription factor-1(TTF-1)
gene: evidence of autoregulation. Endocrinology 139:
1999–2006
53. Perrone L, Tell G, Di Lauro R 1999 Calreticulin enhances
the transcriptional activity of thyroid transcription fac-
tor-1 by binding to its homeodomain. J Biol Chem 274:
4640–4645
54. Dumont JE, Lamy F, Roger P, Maenhaut C 1992 Physi-
ological and pathological regulation of thyroid cell prolif-
eration and differentiation by thyrotropin and other
growth factors. Physiol Rev 72:667–698
55. Dremier S, Pohl V, Poteet-Smith C, Roger PP, Corbin J,
Doskeland SO, Dumont JE, Maenhaut C 1997 Activation
of cyclic AMP-dependent kinase is required but may not
be sufficient to mimic cyclic AMP-dependent DNA syn-
thesis and thyroglobulin expression in dog thyroid cells.
Mol Cell Biol 17:6717–6726
Medina et al. • RhoA and Thyroid Mol Endocrinol, January 2002, 16(1):33–44 43
 by on May 20, 2010 mend.endojournals.orgDownloaded from 
56. Cass LA, Summers SA, Prendergast GV, Backer JM,
Birnbaum MJ, Meinkoth JL 1999 Protein kinase A-
dependent and -independent signaling pathways con-
tribute to cyclic AMP-stimulated proliferation. Mol Cell
Biol 19:5882–5891
57. De Vita G, Berlingieri MT, Visconti R, Castellone MD,
Viglieto G, Baldassarre G, Zannini M, Bellacosa A, Tsich-
lis PN, Fusco A, Santoro M 2000 Akt/Protein kinase B
promotes survival and hormone-independent prolifera-
tion of thyroid cells in the absence of differentiating and
transforming effects. Cancer Res 60:3916–3920
58. Sahai E, Olson MF, Marshall CJ 2001 Cross-talk between
Ras and Rho signalling pathways in transformation
favours proliferation and increase motility EMBO J 20:
755–7666
59. Ambesi-Impiombato FS, Parks LAM, Coon HG 1980 Cul-
ture of hormone-dependent functional cells of rat thyroid.
Proc Natl Acad Sci USA 77:3455–3459
60. Kohn LD, Valente WA, Grollman EF, Aloj SM, Vitti P 1986
Clinical determination and or quantification of thyrotropin
and a variety of thyroid stimulatory and inhibitory factors
performed in vitro with an improved cell line FRTL-5. US
Patent 4:609–622
61. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu
N, Miki T, Gutkind JS 1995 The small GTP-binding pro-
teins Rac1 and Cdc-42 regulate the activity of the JNK/
SAP signalling pathway. Cell 81:1137–1146
62. Brasier AR, Tate JE, Habener JF 1989 Optimized use of
the firefly luciferase assay as a reporter gene in mamma-
lian cell lines. Biotechniques 7:1116–1122
63. Gorman CM, Moffat LM, Howard BH 1982 Recombinant
genomes which express chloramphenicol acetyltrans-
ferase in mammalian cells. Mol Cell Biol 2:1044–1051
64. Bancroft JD, Cook HC 1994 Manual of histological
techniques and their diagnostic application. London:
Churchill Livingstone Editorial
65. Chomczynski P, Sacchi N 1987 Single step method of
RNA isolation by acid guanidinium thiocyanate-phenol-
chloroform extraction. Anal Biochem 162:156–159
66. Di Lauro R, Obici S, Acquaviva AM, Alvino C 1985 The
sequence of 967 amino acids at the carboxi-end of rat
thyroglobulin. Location and surroundings of two thyrox-
ine-forming sites. Eur J Biochem 148:7–11
67. Guazzi S, Price M, De Felice M, Damante G, Mattei MG,
Di Lauro R 1990 Thyroid nuclear factor 1 (TTF-1) contains
a homeodomain and displays a novel DNA binding spec-
ificity. EMBO J 9:3631–3639
68. Levi A, Eldridge JD, Paterson BM 1985 Molecular cloning
of a gene sequence regulated by nerve growth factor.
Science 229:393–395
44 Mol Endocrinol, January 2002, 16(1):33–44 Medina et al. • RhoA and Thyroid
 by on May 20, 2010 mend.endojournals.orgDownloaded from 
